Resistant gram-negative infections

Critical Care Clinics

Volumn 29, Issue 4, 2013, Pages 895-921

  Fraimow, Henry ^a   Nahra, Raquel ^a  

^a Children s Regional Hospital   (United States)

Author keywords

Acinetobacter species; Antibiotic resistance; Enterobacteriaceae; Gram negative bacilli; Pseudomonas aeruginosa; Septic shock

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFEPIME; CEPHALOSPORIN DERIVATIVE; COLISTIN; COTRIMOXAZOLE; DORIPENEM; FOSFOMYCIN; IMIPENEM; MACROLIDE; MINOCYCLINE; MONOBACTAM DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; SULBACTAM; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ENTEROBACTERIACEAE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

ACINETOBACTER SPECIES; ANTIBIOTIC RESISTANCE; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACILLI; PSEUDOMONAS AERUGINOSA; SEPTIC SHOCK;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS;

EID: 84884973243     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2013.06.010     Document Type: Review

References (106)

1. Boucher H.W., Talbot G.H., Bradley J.S., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
2. Livermore D.M. Has the era of untreatable infections arrived?. JAntimicrob Chemother 2009, 64(Suppl 1):i29-i36.
3. Spellberg B., Guidos R., Gilbert D., et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:155-164.
4. Brusselaers N., Vogelaers D., Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 2011, 1:47.
5. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
6. Rosenthal S.L., Freundlich L.F., Quraishi M.A. Sensitivity of gentamicin-resistant Enterobacteriaceae to cefamandole and cefoxitin. Chemotherapy 1979, 25(3):157-162.
7. Koch D.C., Raunest M., Harder T., et al. Unilateral access regulation: ground state dynamics of the Pseudomonas aeruginosa outer membrane efflux duct OprM. Biochemistry 2013, 52(1):178-187.
8. Fraimow H.S., Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin 2011, 27:163-205.
9. Kanj S.S., Kanafani Z.A. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011, 86:250-259.
10. Pillar CM, Brown NP, Sahm DF, etal. Trends towards increased resistance among clinically important gram-negative pathogens in the US; results from 10 years of TRUST surveillance (1999-2009). Abstract C2-696, Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston (MA): 2010. Available at:. Accessed January 23, 2013. http://www.eurofins.com/media/1770121/C2-696.pdf.
11. Yang Q., Wang H., Chen M., et al. Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002-2009 Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2010, 36:507-512.
12. Kallen A.J., Hidron A.I., Patel J., et al. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010, 31:528-531.
13. Zhanel G.G., DeCorby M., Laing N., et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008, 52:1430-1437.
14. Rosenthal V.D., Bijie H., Maki D.G., et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012, 40:396-407.
15. Borer A., Saidel-Odes L., Eskira S., et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospitalized patients initially only colonized with carbapenem resistant K. pneumoniae. Am J Infect Control 2012, 40:421-425.
16. Available at:. Accessed January 23, 2013. http://www.cdc.gov/hai/eip/mugsi_techinfo.html.
17. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. JMed Microbiol 2006, 55:1619-1629.
18. Goossens H. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect 2003, 9:980-983.
19. Falagas M.E., Karageorgopoulos D.E. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008, 46:1121-1122.
20. Apisarnthanarak A., Pinitchai U., Thongphubeth K., et al. Amultifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study. Clin Infect Dis 2008, 47:760-767.
21. Doi Y., Husain S., Potoski B.A., et al. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009, 15:980-982.
22. Park Y.K., Peck K.R., Cheong H.S., et al. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009, 15:1325-1327.
23. Magiorakos A.P., Srinivasan A., Carey R.B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18(3):268-281.
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement CLSI document M100-S20. Wayne (PA): Clinical and Laboratory Standards Institute.
25. Esterly J.S., Wagner J., McLaughlin M.M., et al. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother 2012, 56(9):4885-4890.
26. Defife R., Scheetz M.H., Feinglass J.M., et al. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob Agents Chemother 2009, 53(3):1074-1079.
27. Kosmidis C., Poulakou G., Markogiannakis A. Treatment options for infections caused by carbapenem-resistant gram negative bacteria. Eur Infect Dis 2012, 6:28-34.
28. Michalopoulos A., Falagas M.E. Colistin and polymyxin B in critical care. Crit Care Clin 2008, 24:377-391.
29. Drusano G.L., Lodise T.P. Editorial commentary: saving lives with optimal antimicrobial chemotherapy. Clin Infect Dis 2013, 56:245-247.
30. Falagas M.E., Tansarli G.S., Ikawa K., et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and Piperacillin/Tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013, 56:272-282.
31. Wood G.C. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2011, 9:993-1000.
32. Beardsley J.R., Williamson J.C., Johnson J.W., et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006, 130:787-793.
33. Mandell L. Doripenem: a new carbapenem in the treatment of nosocomial infection. Clin Infect Dis 2009, 49(Suppl 1):S1-S3.
34. Urban C., Mariano N., Rahal J.J. Invitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010, 54:2732-2734.
35. Livermore D.M. Tigecycline: what is it, and where should it be used?. JAntimicrob Chemother 2005, 56:611-614.
36. Wang Y.F., Dowzicky M.J. Invitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008. Diagn Microbiol Infect Dis 2010, 68:73-79.
37. Burkhardt O., Rauch K., Kaever V., et al. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009, 34:101-102.
38. Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect 2012, 18:4-7.
39. Falagas M.E., Kastoris A.C., Kapaskelis A.M., et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010, 10:43-50.
40. Arroyo L.A., Mateos I., Gonzalez V., et al. Invitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009, 53:1295-1296.
41. Jankowski C.A., Balada-Liasat J. Astewardship approach to combating multidrug-resistant Acinetobacter infections with minocycline. Infect Dis Clin Pract (Baltim Md) 2012, 20:184-187.
42. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538-582.
43. Fishbain J., Peleg A.Y. Treatment of Acinetobacter infections. Clin Infect Dis 2010, 51:79-84.
44. Shakil S., Azhar E.I., Tabrez S., et al. New Delhi metallo-beta-lactamase (NDM-1): an update. JChemother 2011, 23:263-265.
45. Drapeau C.M., Grilli E., Petrosillo N. Rifampicin combined regimens for gram-negative infections: data from the literature. Int J Antimicrob Agents 2010, 35:39-44.
46. Yahav D., Farbman L., Leibovici L., et al. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012, 18:18-29.
47. Nation R.L., Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009, 22:535-543.
48. Cai Y., Chai D., Wang R., et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. JAntimicrob Chemother 2012, 67:1607-1615.
49. Garonzik S.M., Li J., Thamlikitkul V., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55:3284-3294.
50. Freire-Moran L., Aronsson B., Manz C., et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-time to react is now. Drug Resist Updat 2011, 14:118-124.
51. Florescu D.F., Qiu F., McCartan M.A., et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012, 54:670-680.
52. Trial for the treatment of extensively drug-resistant gram-negative bacilli. Available at:. Accessed January 24, 2013. http://clinicaltrials.gov/ct2/show/NCT01597973.
53. Multicenter open-label randomized controlled trial (RCT) to compare colistin alone versus colistin plus meropenem. Available at:. Accessed January 24, 2013. http://clinicaltrials.gov/ct2/show/NCT01732250.
54. Abdul-Aziz M.H., Dulhunty J.M., Bellomo R., et al. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care 2012, 2:37.
55. George J.M., Colton B.J., Rodvold K.A. National survey on continuous and extended infusions of antibiotics. Am J Health Syst Pharm 2012, 69:1895-1904.
56. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
57. Dulhunty J.M., Roberts J.A., Davis J.S., et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013, 56:236-244.
58. Hallal A., Cohn S.M., Namias N., et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt) 2007, 8:73-82.
59. Czosnowski Q.A., Wood G.C., Magnotti L.J., et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009, 29:1054-1060.
60. Mohr A.M., Sifri Z.C., Horng H.S., et al. Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. Surg Infect (Larchmt) 2007, 8:349-357.
61. Kofteridis D.P., Alexopoulou C., Valachis A., et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010, 51:1238-1244.
62. Paterson D.L., Ko W.C., Von Gottberg A., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004, 39:31-37.
63. Peleg A.Y., Hooper D.C. Hospital-acquired infections due to gram-negative bacteria. NEngl J Med 2010, 362:1804-1813.
64. Pitout J.D. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010, 70:313-333.
65. Vardakas K.Z., Tansarli G.S., Rafailidis P.I., et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. JAntimicrob Chemother 2012, 67:2793-2803.
66. Lye D.C., Wijaya L., Chan J., et al. Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia. Ann Acad Med Singapore 2008, 37:831-834.
67. Gavin P.J., Suseno M.T., Thomson R.B., et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006, 50:2244-2247.
68. Labombardi V.J., Rojtman A., Tran K. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis 2006, 56:313-315.
69. Bin C., Hui W., Renyuan Z., et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 2006, 56:351-357.
70. Lee N.Y., Lee C.C., Huang W.H., et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013, 56:488-495.
71. Endimiani A., Luzzaro F., Perilli M., et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004, 38:243-251.
72. Kim Y.K., Pai H., Lee H.J., et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002, 46:1481-1491.
73. Chow J.W., Fine M.J., Shlaes D.M., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
74. Jacoby G.A. AmpC beta-lactamases. Clin Microbiol Rev 2009, 22:161-182.
75. Tzouvelekis L.S., Markogiannakis A., Psichogiou M., et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25:682-707.
76. Ben-David D., Kordevani R., Keller N., et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012, 18:54-60.
77. Souli M., Galani I., Antoniadou A., et al. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010, 50:364-373.
78. Daikos G.L., Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin Microbiol Infect 2011, 17:1135-1141.
79. Elemam A., Rahimian J., Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009, 49:271-274.
80. Bratu S., Tolaney P., Karumudi U., et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and invitro activity of polymyxin B and other agents. JAntimicrob Chemother 2005, 56:128-132.
81. Elemam A., Rahimian J., Doymaz M. Invitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. JClin Microbiol 2010, 48:3558-3562.
82. Bulik C.C., Nicolau D.P. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011, 55:3002-3004.
83. Lee Y.T., Kuo S.C., Yang S.P., et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 2012, 55:209-215.
84. Gales A.C., Jones R.N., Sader H.S. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). JAntimicrob Chemother 2011, 66:2070-2074.
85. Manchanda V., Sanchaita S., Singh N. Multidrug resistant Acinetobacter. JGlob Infect Dis 2010, 2:291-304.
86. Paterson D.L., Depestel D.D. Doripenem. Clin Infect Dis 2009, 49:291-298.
87. Lee N.Y., Wang C.L., Chuang Y.C., et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an invitro combination synergy study. Pharmacotherapy 2007, 27:1506-1511.
88. Garnacho-Montero J., Ortiz-Leyba C., Jimenez-Jimenez F.J., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003, 36:1111-1118.
89. Bassetti M., Repetto E., Righi E., et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. JAntimicrob Chemother 2008, 61:417-420.
90. Gordon N.C., Png K., Wareham D.W. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54:5316-5322.
91. Petrosillo N., Ioannidou E., Falagas M.E. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008, 14:816-827.
92. Poulakou G., Kontopidou F.V., Paramythiotou E., et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. JInfect 2009, 58:273-284.
93. Cascio A., Conti A., Sinardi L., et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis 2010, 14:e572-e579.
94. Tam V.H., Rogers C.A., Chang K.T., et al. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010, 54:3717-3722.
95. Croughs P.D., Li B., Hoogkamp-Korstanje J.A., et al. Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands. Eur J Clin Microbiol Infect Dis 2012, 32(2):283-288.
96. Riera E., Cabot G., Mulet X., et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. JAntimicrob Chemother 2011, 66:2022-2027.
97. Durakovic N., Radojcic V., Boban A., et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med 2011, 50:1009-1013.
98. Kvitko C.H., Rigatto M.H., Moro A.L., et al. Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. JAntimicrob Chemother 2011, 66:175-179.
99. Lee J.Y., Song J.H., Ko K.S. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea. Microb Drug Resist 2011, 17:299-304.
100. Chamot E., Boffi El Amari E., Rohner P., et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003, 47:2756-2764.
101. Apisarnthanarak A., Mundy L.M. Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia. Clin Infect Dis 2010, 51:1352-1354.
102. Nicodemo A.C., Paez J.I. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007, 26:229-237.
103. Insa R., Cercenado E., Goyanes M.J., et al. Invitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. JAntimicrob Chemother 2007, 59:583-585.
104. Marshall J.C., Maier R.V., Jimenez M., et al. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004, 32:S513-S526.
105. Sulaiman L., Hunter J., Farquharson F., et al. Mechanical thrombectomy of an infected deep venous thrombosis: a novel technique of source control in sepsis. Br J Anaesth 2011, 106:65-68.
106. Rennie RP, Turnbull L, Johnson A. Surveillance of gram-negative intra-abdominal and urinary tract pathogens in Canada compared to the rest of the world: the SMART study Abstract C2-1789, Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago (IL): 2011.